Welcome to our dedicated page for Merus SEC filings (Ticker: MRUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Multispecific antibodies may revolutionize cancer therapy, but the disclosures behind Merus N.V.’s Biclonics® platform are anything but simple. From detailed phase 1/2 trial updates to collaboration milestone accounting, Merus filings can overwhelm even seasoned biotech analysts.
Stock Titan’s AI-powered analysis turns that complexity into clarity. Need the Merus quarterly earnings report 10-Q filing? We surface R&D burn rates and cash runway in seconds. Hunting for Merus insider trading Form 4 transactions or monitoring Merus executive stock transactions Form 4? Real-time alerts appear moments after EDGAR posts—no manual refresh required. Our platform also delivers plain-English digests so you’re understanding Merus SEC documents with AI rather than wading through legal jargon.
Every submission, from an 8-K announcing fresh clinical data to the comprehensive 10-K, is mapped to the questions investors actually ask:
- Merus annual report 10-K simplified – find pipeline timelines, collaboration revenue splits, and risk factors in one click.
- Merus 8-K material events explained – track trial readouts, FDA designations, or new licensing deals instantly.
- Merus proxy statement executive compensation – compare leadership incentives to R&D milestones.
Whether you’re performing a quick Merus earnings report filing analysis or need Merus Form 4 insider transactions real-time, Stock Titan provides comprehensive coverage and AI-generated summaries that answer, "Are insiders buying ahead of data?" or "How long will cash last at current burn?" Investors save hours, gain confidence, and never miss a disclosure that could move the stock.
Commodore Capital LP and Commodore Capital Master LP reported beneficial ownership of 3,525,000 common shares of Merus N.V. (CUSIP N5749R100), equal to 4.7% of the 75,565,138 shares outstanding used for the calculation. The filing shows shared voting power and shared dispositive power over all 3,525,000 shares and no sole voting or dispositive power. The Firm (Commodore Capital LP) is the investment manager to Commodore Capital Master LP, and Michael Kramarz and Robert Egen Atkinson are the managing partners who exercise investment discretion. The filing includes a certification that the shares were not acquired to change or influence control of Merus.
Merus N.V. (Common Stock, CUSIP N5749R100) is the subject of a Schedule 13G/A filed by Wellington entities reporting aggregate beneficial ownership of 3,726,723 shares, representing 5.01% of the class. The filing shows shared voting power of 3,358,050 shares and shared dispositive power of 3,726,723 shares, with no sole voting or dispositive power reported. The securities are owned of record by clients of Wellington's investment advisers and are described as held in the ordinary course of business; the filing certifies they were not acquired to change or influence control of the issuer.
Peter B. Silverman, COO & General Counsel of Merus N.V. (MRUS), executed a planned transaction under Rule 10b5-1 on June 20, 2025. The transaction involved:
- Exercise of 34,000 stock options at $18.61 per share
- Immediate sale of all 34,000 shares at a weighted average price of $52.76 (range: $52.44-$53.06)
- Retained 23,500 unexercised options from original February 14, 2020 grant
This transaction was conducted according to a pre-established Rule 10b5-1 trading plan adopted on March 20, 2025. The exercised options were fully vested, with an original expiration date of February 14, 2030. The sale represents a significant realization of gains, with approximately $1.16 million in gross proceeds before accounting for the exercise cost of $632,740.
FAQ
What is the current stock price of Merus (MRUS)?
What is the market cap of Merus (MRUS)?
